Abbott India Limited
ABBOTINDIA · Pharma · NSE
₹25,845
Current Market Price
Fair Value (DCF)
₹22,604
Margin of Safety
-12.5%
Updated just now
YieldIQ Score
58/100
Piotroski F-Score
7/9
Economic Moat
Wide
Confidence
84%
ROE
33.4%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.55 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
42.1%
Return on capital employed
EV / EBITDA
25.4×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
166.1×
EBIT covers interest
Current Ratio
3.39×
Short-term liquidity
Asset Turnover
1.20×
Revenue per ₹ of assets
Revenue CAGR (3Y)
8.5%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹25,845
Bear case
₹12,188.27
MoS -112.0%
Base case
₹22,604.24
MoS -14.3%
Bull case
₹27,533.54
MoS +6.1%
Ratio Trends
ABBOTINDIA · last 4 annual periods
ROE
33.4%
ROCE
44.5%
Operating Margin
—
Debt / Equity
0.05×
PE
49.4×
EV / EBITDA
34.4×
Historical Financials
ABBOTINDIA · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹4910 Cr | ₹5347 Cr | ₹5847 Cr | ₹6407 Cr | +9.3% |
| EBITDA | ₹1165 Cr | ₹1360 Cr | ₹1701 Cr | ₹1970 Cr | +19.1% |
| EBIT | — | — | — | — | — |
| PAT | ₹799 Cr | ₹949 Cr | ₹1201 Cr | ₹1414 Cr | +21.0% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹948 Cr | ₹893 Cr | ₹1213 Cr | ₹1012 Cr | +2.2% |
| CapEx | ₹-44.1 Cr | ₹-34.1 Cr | ₹-48.3 Cr | ₹-52.6 Cr | — |
| FCF | ₹904 Cr | ₹859 Cr | ₹1164 Cr | ₹959 Cr | +2.0% |
| Total Assets | ₹4224 Cr | ₹4556 Cr | ₹5193 Cr | ₹5917 Cr | +11.9% |
| Total Debt | ₹152 Cr | ₹113 Cr | ₹83.2 Cr | ₹197 Cr | +9.0% |
| Shareholders' Equity | ₹2820 Cr | ₹3189 Cr | ₹3699 Cr | ₹4233 Cr | +14.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ABBOTINDIA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| LAURUSLABS Laurus Labs Limited | -63.3% | 40 | Data Limited | 7.8% | — |
| GLENMARK Glenmark Pharmaceuticals Limited | -40.5% | 46 | Data Limited | 11.8% | — |
| ALKEM Alkem Laboratories Limited | +4.1% | 51 | Fairly valued | 17.4% | — |
| IPCALAB IPCALAB | — | — | Pending | 8.8% | — |
| AUROPHARMA Aurobindo Pharma Limited | +36.3% | 59 | Undervalued | 10.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹1,760.00/sh
Last payout
2025-07-25
₹475.00
Peak payout
₹475.00
Trailing yield
1.84%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Abbott India Limited (ABBOTINDIA.NS) trades at 25845.00 vs a model fair value of 22604.24, a gap of -12.5%. Piotroski F-score: 7/9. Moat ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ABBOTINDIA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ABBOTINDIA →
Compare
Head-to-head with peers
Compare ABBOTINDIA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ABBOTINDIANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.